2020
Clinical and Genome-Wide Analysis of Multiple Severe Cisplatin-Induced Neurotoxicities in Adult-Onset Cancer Survivors
Trendowski MR, Wheeler HE, El-Charif O, Feldman DR, Hamilton RJ, Vaughn DJ, Fung C, Kollmannsberger C, Einhorn LH, Travis LB, Dolan ME. Clinical and Genome-Wide Analysis of Multiple Severe Cisplatin-Induced Neurotoxicities in Adult-Onset Cancer Survivors. Clinical Cancer Research 2020, 26: 6550-6558. PMID: 32998964, PMCID: PMC7744329, DOI: 10.1158/1078-0432.ccr-20-2682.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBleomycinCancer SurvivorsCisplatinEtoposideFemaleFollow-Up StudiesGene Expression Regulation, NeoplasticGenome-Wide Association StudyHumansIfosfamideMaleMiddle AgedNeoplasmsNeurotoxicity SyndromesPolymorphism, Single NucleotidePrognosisRisk FactorsSurvival RateVinblastineConceptsCumulative cisplatin doseCisplatin doseSevere neurotoxicityCancer survivorsRisk factorsAdult-onset cancer survivorsLifestyle/behavioral factorsCisplatin-induced neurotoxicityDizziness/vertigoNeuro-otological symptomsPeripheral sensory neuropathyPoor overall healthPeripheral motor neuropathyImportant risk factorTesticular cancer survivorsQuality of lifeSerum platinum levelsDose adjustmentMotor neuropathyRaynaud's phenomenonSensory neuropathyNeurotoxicity riskPsychotropic medicationsClinical examinationMedical history
2012
Risk of Venous Thromboembolism in Patients With Cancer Treated With Cisplatin: A Systematic Review and Meta-Analysis
Seng S, Liu Z, Chiu S, Proverbs-Singh T, Sonpavde G, Choueiri T, Tsao C, Yu M, Hahn N, Oh W, Galsky M. Risk of Venous Thromboembolism in Patients With Cancer Treated With Cisplatin: A Systematic Review and Meta-Analysis. Journal Of Clinical Oncology 2012, 30: 4416-4426. PMID: 23150697, DOI: 10.1200/jco.2012.42.4358.Peer-Reviewed Original ResearchConceptsRisk of venous thromboembolic eventsCisplatin-based chemotherapyVenous thromboembolic eventsNon-cisplatin-based chemotherapySolid tumorsRandomized Controlled TrialsIncreased risk of VTENon-cisplatin-based regimensIncreased riskPatients treated with cisplatin-based chemotherapyIncidence of venous thromboembolic eventsIncreased risk of thromboembolismMeta-analysis of randomized controlled trialsRisk of venous thromboembolismControlled TrialsAdvanced solid tumorsMeta-analysisRisk of thromboembolismExploratory subgroup analysisRandom-effects modelCisplatin-basedCisplatin doseIII trialsThromboembolic eventsVenous thromboembolismRisk of venous thromboembolism in cancer patients treated with cisplatin: A systematic review and meta-analysis.
Seng S, Liu Z, Chiu S, Proverbs-Singh T, Sonpavde G, Choueiri T, Tsao C, Yu M, Hahn N, Oh W, Galsky M. Risk of venous thromboembolism in cancer patients treated with cisplatin: A systematic review and meta-analysis. Journal Of Clinical Oncology 2012, 30: e21016-e21016. DOI: 10.1200/jco.2012.30.15_suppl.e21016.Peer-Reviewed Original ResearchRisk of venous thromboembolic eventsCisplatin-based chemotherapyVenous thromboembolic eventsPatients treated with cisplatin-based chemotherapyRandomized Controlled TrialsAdvanced solid tumorsThromboembolic eventsSolid tumorsCisplatin doseMeta-analysisIncreased risk of VTESubgroup analysisConfidence intervalsNon-cisplatin-based chemotherapyIncreased riskIncidence of venous thromboembolic eventsCancer patients treated with cisplatinPatients treated with cisplatinIncreased risk of thromboembolismMeta-analysis of randomized controlled trialsRisk of venous thromboembolismNon-cisplatin chemotherapyRisk of thromboembolismTrial of patientsHigher relative risk
2000
Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer.
Kaufman D, Raghavan D, Carducci M, Levine E, Murphy B, Aisner J, Kuzel T, Nicol S, Oh W, Stadler W. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. Journal Of Clinical Oncology 2000, 18: 1921-7. PMID: 10784633, DOI: 10.1200/jco.2000.18.9.1921.Peer-Reviewed Original ResearchConceptsMetastatic urothelial cancerTreatment of metastatic urothelial cancerChemotherapy-naive patientsUrothelial cancerMedian time to treatment failurePhase II trial of gemcitabineTreatment of chemotherapy-naive patientsDay 1Time to treatment failureStage IV carcinomaTrial of gemcitabineCombination of gemcitabinePhase II trialClinical safety profileHematologic toxicityCisplatin doseIV carcinomaPartial responseMedian survivalTreatment failureSafety profileSevere toxicityGemcitabineChemotherapeutic agentsDisease progression
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply